NZ546286A - Process for producing 1,4-dihydroxy-2-naphthoic acid - Google Patents
Process for producing 1,4-dihydroxy-2-naphthoic acidInfo
- Publication number
- NZ546286A NZ546286A NZ546286A NZ54628604A NZ546286A NZ 546286 A NZ546286 A NZ 546286A NZ 546286 A NZ546286 A NZ 546286A NZ 54628604 A NZ54628604 A NZ 54628604A NZ 546286 A NZ546286 A NZ 546286A
- Authority
- NZ
- New Zealand
- Prior art keywords
- culture
- medium
- producing
- dihydroxy
- carbon source
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 37
- VOJUXHHACRXLTD-UHFFFAOYSA-N 1,4-dihydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC(O)=C21 VOJUXHHACRXLTD-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 230000008569 process Effects 0.000 title claims abstract description 22
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 74
- 241000894006 Bacteria Species 0.000 claims abstract description 45
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 37
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 37
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 238000012258 culturing Methods 0.000 claims abstract description 17
- 208000020084 Bone disease Diseases 0.000 claims abstract description 11
- 206010000059 abdominal discomfort Diseases 0.000 claims abstract description 11
- 230000002503 metabolic effect Effects 0.000 claims abstract description 10
- 238000005273 aeration Methods 0.000 claims description 42
- 230000000977 initiatory effect Effects 0.000 claims description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 239000007789 gas Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 claims 1
- 102100035353 Cyclin-dependent kinase 2-associated protein 1 Human genes 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- VOJUXHHACRXLTD-UHFFFAOYSA-M 1,4-dihydroxy-2-naphthoate Chemical compound C1=CC=C2C(O)=CC(C([O-])=O)=C(O)C2=C1 VOJUXHHACRXLTD-UHFFFAOYSA-M 0.000 description 57
- 108010065780 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase Proteins 0.000 description 57
- 108010089355 dihydroneopterin aldolase Proteins 0.000 description 57
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 32
- 239000008101 lactose Substances 0.000 description 31
- 235000002639 sodium chloride Nutrition 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 108091005804 Peptidases Proteins 0.000 description 13
- 235000020183 skimmed milk Nutrition 0.000 description 13
- 239000004365 Protease Substances 0.000 description 12
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102000007544 Whey Proteins Human genes 0.000 description 11
- 108010046377 Whey Proteins Proteins 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 235000013618 yogurt Nutrition 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000009423 ventilation Methods 0.000 description 9
- 241000186428 Propionibacterium freudenreichii Species 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 239000005862 Whey Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 6
- 235000010378 sodium ascorbate Nutrition 0.000 description 6
- 229960005055 sodium ascorbate Drugs 0.000 description 6
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- -1 for example Chemical class 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000007065 protein hydrolysis Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 235000021119 whey protein Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 235000019631 acid taste sensations Nutrition 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 101710180316 Protease 2 Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000010350 erythorbic acid Nutrition 0.000 description 2
- 239000004318 erythorbic acid Substances 0.000 description 2
- 238000004401 flow injection analysis Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940026239 isoascorbic acid Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000186426 Acidipropionibacterium acidipropionici Species 0.000 description 1
- 241000186425 Acidipropionibacterium jensenii Species 0.000 description 1
- 241000186335 Acidipropionibacterium thoenii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 241001464974 Cutibacterium avidum Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241001464976 Propionimicrobium lymphophilum Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Chemical group 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000012770 industrial material Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical group CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 229940055009 propionibacterium avidum Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Chemical group 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
- A23C9/1209—Proteolytic or milk coagulating enzymes, e.g. trypsine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Disclosed is a process for producing 1,4-dihydroxy-2-naphthoic acid comprising culturing propionic acid bacteria in a medium comprising 4 to 8 % mass of a carbon source under anaerobic conditions, and aerating the medium when the concentration of a carbon source in the medium reaches 3.5% by mass or less. Compositions obtained by the process can be used for treating metabolic osteopathy or improving abdominal discomfort.
Description
<div class="application article clearfix" id="description">
<p class="printTableText" lang="en">546286 <br><br>
- 1 - <br><br>
DESCRIPTION <br><br>
PROCESS FOR PRODUCING 1,4—DIHYDROXY~2—NAPHTHOIC ACID <br><br>
Technical Field <br><br>
The present invention relates to a process for producing a high concentration of 1,4-dihydroxy-2-naphthoic acid (hereinafter it may be referred to as DHNA) using a propionic acid-bacterial fermentation and a technique for improving flavor of the culture thereof. <br><br>
Background Art <br><br>
DHNA has been known to be useful for industrial materials as dyes, pigments or photographic sensitive materials, and heretofore various synthetic methods by organic chemical synthesis have been developed. As a result of extensive studies by the inventors of the present invention on alternative method for production of DHNA, they have found that a large amount of DHNA could be produced by propionic acid bacteria in or outside the cell and they have found that a composition containing DHNA, or 1,4-dihydroxy-2-naphthoic acid or a salt thereof isolated from the culture had an action for reducing abdominal discomfort caused by lactose intolerance observed at the time of ingestion of milk and at the same time it was useful for prevention and treatment of metabolic bone disease (Patent document 1). <br><br>
Although according to such a method, it has become possible to use DHNA for beverages and pharmaceutical products, <br><br>
INTELLECTUAL PROPERTY . <br><br>
OFFICE OF N.Z. <br><br>
" 3 APR 2006 HEGilVfcn <br><br>
546286 <br><br>
- 2 - <br><br>
the composition containing DHNA is not always satisfactory in terms of flavour and as a result it has been difficult to use it frequently for commercial products. <br><br>
[Patent document 1]: WO 03/016544 5 The discussion of documents, acts, materials, <br><br>
devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part 10 of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application. <br><br>
Throughout the description and claims of this 15 specification, use of the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps. <br><br>
20 Disclosure of the Invention <br><br>
Problem to be Solved by the Invention <br><br>
An aspect of the present invention is to provide an effective process for production of a composition containing DHNA, which is improved in flavor, by the 25 propionic acid fermentation. <br><br>
Means for Solving the Problem <br><br>
The present inventors have obtained unexpectedly, as a result of extensive studies from the standpoint of various fields in order to obtain composition containing 30 DHNA with suppressed bitter taste, useful novel knowledge indicating that the concentration of DHNA in the culture was increased by aeration in the medium at a specific period during the propionic acid fermentation. The <br><br>
W:\SEW\NZ147l8-06 (GYQMst responsetepeci-0iCKI08.cloc <br><br>
INTELLECTUAL PRO|lRtY <br><br>
OFFICE <br><br>
16 sep m ocr.FlVED <br><br>
546286 <br><br>
- 2a - <br><br>
inventors have also found that the concentration of DHNA was increased by adding nutrient carbon sources of propionic acid bacteria in the culture after the cultivation and let it stand at low-temperature under weak 5 alkaline conditions, even after culturing was terminated. In addition, the inventors have found that bitterness of thus obtained composition containing DHNA wa.s suppressed and thus the flavor was improved; and for this, it was found useful for food, beverages or pharmaceutical 10 products. <br><br>
In one aspect, the present invention provides a process for producing 1,4-dihydroxy-2-naphthoic acid comprising initiating the culture of 1,4-dihydroxy-2-naphthoic acid producing bacteria belonging to propionic 15 acid bacteria in a medium comprising 4 to 8 % mass of a carbon source under anaerobic conditions and culturing the bacteria under aeration into the medium when the concentration of a carbon source in the medium is 3.5% by mass or less. <br><br>
20 In another aspect, the present invention provides a process for producing 1,4-dihydroxy-2-naphthoic acid, comprising initiating the culture of 1,4-dihydroxy-2-naphthoic acid producing bacteria belonging to propionic acid bacteria in a medium comprising 4 to 8% by mass of a 25 carbon source under anaerobic conditions, culturing the bacteria under aeration into a medium when the concentration of a carbon source in the medium is 3.5% by mass or less, adding the carbon source to the obtained culture and preserving the culture at 3 to 20°C under weak 30 alkaline conditions. <br><br>
W:\Sew\NZ147ie«0e (GYQVIst response\sped-010806.doc <br><br>
546286 <br><br>
- 3 - <br><br>
The present invention provides a process for producing 1,4-dihydroxy-2-naphthoic acid comprising culturing the 1,4-dihydroxy-2-napthoic acid producing bacteria belonging to the propionic acid bacteria first 5 under anaerobic conditions and initiating aeration in a medium when the concentration of a carbon source in the medium is 3.5% or less by mass. <br><br>
The present invention also provides a process for producing 1,4-dihydroxy-2-napthoic acid comprising 10 culturing 1, 4-dihydroxy-2-napthoic acid producing bacteria belonging to propionic acid bacteria under anaerobic conditions, adding a carbon source to the obtained culture and preserving the culture at 3 to 20°C under weak alkaline conditions. <br><br>
15 The present invention further provides a process for producing 1, ■4-dihydroxy-2-napthpic acid comprising initiating the culture of 1,4-dihydroxy-2-napthoic acid producing bacteria belonging to propionic acid bacteria under anaerobic conditions, culturing the bacteria with 20 aeration in a medium when the concentration of a carbon source in the medium is 3.5% by mass or less, adding the carbon source to the obtained culture and preserving the culture at 3 to 20°C under weak alkaline conditions. <br><br>
The present invention further provides a composition 25 containing 1,4-dihydroxy-2-napthoic acid obtained as described hereinabove. <br><br>
The present invention further provides food and beverages for improving abdominal discomfort, an agent for improving abdominal discomfort, food and beverages for 30 preventing and <br><br>
W:\SEW\NZ14718-06 <GYC)\tst resporweVsDect-010808.doc llNTE'' P^TUAL PROPERTY I <br><br>
' office OF ISU <br><br>
1 6 SEP 2008 iRECEIVJ <br><br>
546286 <br><br>
- 4 - <br><br>
treating metabolic osteopathy, or an agent for preventing andtreatingmetabolic osteopathy, comprising the composition containing 1,4-dihydroxy-2-naphthoic acid as an active ingredient obtained as described hereinabove. <br><br>
The present invention further provides use of the composition containing 1,4-dihydroxy-2-naphthoic acid obtained as described hereinabove for producing food and beverages for improving abdominal discomfort, an agent for improving abdominal discomfort, food and beverages for preventing and treating metabolic osteopathy or an agent for preventing and treating metabolic osteopathy. <br><br>
The present invention further provides a method for treating abdominal discomfort or a method for treating metabolic osteopathy comprising administering an effective amount of the composition containing <br><br>
1,4-dihydroxy-2-naphthoic acid obtained as described hereinabove. <br><br>
Advantage of the invention <br><br>
According to the present invention, DHNA can be produced efficiently and a composition containing the obtained DHNA has a good flavor and is useful for food, beverages and pharmaceuticals. <br><br>
Brief Description of the Drawings <br><br>
Figure 1 shows changes in concentration of DHNA due to varied initiation times of aeration; <br><br>
Figure 2 shows changes in concentration of lactose due to varied initiation times of aeration; <br><br>
546286 <br><br>
- 5 - <br><br>
Figure 3 shows relationship between the initiation time of aeration and number of propionic acid bacteria; <br><br>
Figure 4 shows concentration of propionic acid due to varied initiation times of aeration; <br><br>
Figure 5 shows concentration of acetic acid due to varied initiation times of aeration; and <br><br>
Figure 6 shows concentration of DHNA due to varied initiation times of aeration. <br><br>
Best Mode for Carrying Out the Invention <br><br>
Examples of propionic acid bacteria used for the process for production of the present invention are not specifically limited as long as it is DHNA producing bacteria, and are microorganisms belonging to genus Propionibacterium, for example bacteria for production of cheese such as Propionibacterium freudenreichii, Propionibacterium thoenii, Propionibacterium acidipropionici and Propionibacterium jensenii, and Propionibacterium avidum, Propionibacterium acnes, Propionibacterium lymphophilum and Propionibacterium granulosam. Among them, Propionibacterium freudenreichii is preferable and P. freudenreichii IFO 12424, P. freudenreichii ATCC 6207 and P. freudenreichii ET-3 (FERM P-18454) are particularly preferable. <br><br>
Medium used for the method of the present invention is preferably a medium containing carbon source. The carbon source used in the present invention means assimilable carbon source for propionic acid bacteria. For example, lactose, <br><br>
546286 <br><br>
- 6 - <br><br>
glucose, lactic acid, glycerol, gluten, cellulose, etc. can be mentioned, and lactose is especially preferable. Amount of carbon source content in the medium before initiation of the culture is 4 to 8% by mass, preferably 4 to 7% by mass, more preferably 4 to 6.7% by mass. Among them, examples of the medium, which contains lactose as the carbon source, are whey powder, casein, skim milk, or whey protein concentrate, which is a product having a reduced lactose content obtainable by dialyzing the whey, or a whey protein-separate, which is a highly purified product with highly separated lactose content. These substances can be used without modification, or they can be used with protease treatment, and the medium can be prepared by adding yeast extract, peptone such as tripticase, proper quantity of saccharides, for example, monosaccharide and/or disaccharide, which can be assimilable carbon source for propionic acid bacteria, such as glucose, lactose or lactose treated with lactase, lactic acid, glycerol, gluten, cellulose, mineral such as whey mineral, and if required, animal and plant foodstuff containing rich minerals such as oyster and ginger, or extract thereof. An embodiment of a method for preparing a medium having as a main component of its raw material a protease-treated skim milk is shown hereinbelow. <br><br>
Skim milk is dissolved in water to result in 10 to 20% by mass and temperature was adjusted at 47°C. Protease corresponding to 2.5% by mass of the amount of skim milk was added thereto for hydrolysis of protein in the skim milk solution. Examples of protease are proteolytic enzyme <br><br>
546286 <br><br>
- 7 - <br><br>
derived from animal and plant origin or bacteria origin, and any of acidic, neutral or alkaline protease can be used. Hydrolysis is performed for 6 hours, and temperature during the hydrolysis is maintained at 47°C and pH is adjusted to 6.8. For adjusting pH, aqueous solution of potassium carbonate is used. When the hydrolysis with protease is finished, the skim milk solution is heated to 80°C and maintained for 10 minutes to inactivate the protease. After the inactivation, water is added so that the concentration of the skim milk becomes 10% by mass, and brewer's yeast weighing 1 to 10% by mass of the skim milk, preferably 3 to 7% by mass, is added and then sterilized. Sterilizing condition is at 121°C for 7 minutes or more in case of using autoclave, and 140°C or more for 4 seconds or more in case of using plate for sterilization. The thus obtained medium contains generally 4 to 5% by mass of lactose. <br><br>
Culture is performed under anaerobic conditions. The anaerobic condition can be performed by using nitrogen gas, helium gas, argon gas, hydrogen gas and other inert gas, alone or in combination with one or two or more, and among them, the condition under nitrogen gas or carbon dioxide gas atmosphere is preferable. More concretely, nitrogen gas, carbon dioxide gas, etc. are flowed through top surface in the fermenter with stirring and temperature of medium is adjusted to 33°C. When the temperature of the medium is stabilized at 33°C, propionic acid bacteria starter is inoculated to initiate the culture under anaerobic conditions Activation culture liquid of propionic acid bacteria, <br><br>
546286 <br><br>
- 8 - <br><br>
microbial cell concentrate of the culture liquid can be used as the starter. Amount to be added in the medium is about 0.05% in the former case with respect to the medium and about 0.3% in the latter case only as a guide, however these amounts can be changed if necessary. <br><br>
Culture can be performed under condition of culturing temperature at 20 to 40°C and pH of the medium with neutral or weakly acidic, preferably at pH 5 . 5 to 7.5. For suppressing increase of acidity during the culture, known neutralizing agent such as aqueous potassium carbonate solution, aqueous sodium carbonate solution, etc. can be used. <br><br>
A method for aerating to the medium will be explained hereinbelow. It is particularly surprising in view of the fact that amount of DHNA production is increased by such a means. Reasons for increase of the amount of DHNA production by continuous aeration have not been revealed; however, propionic acid bacteria initiates consumption of propionic acid by such an aeration. <br><br>
Time for initiating aeration is when the concentration of carbon source in the medium reaches 3.5% by mass or less, and the time 24 hours before the carbon source for propionic acid bacteria has been used up can be used as a target for the initiation of the aeration. Time for initiating aeration is preferably at the time when concentration of the carbon source reaches 1.0 to 3.5% by mass, more preferably 1.5 to 3.0% by mass. Aeration at the time, when the concentration of carbon source reaches 3.5% by mass or less, makes the propionic acid bacteria to consume propionic acid in addition <br><br>
546286 <br><br>
- 9 - <br><br>
to the carbon source, and finally the carbon source will almost be used up. Numbers of propionic acid bacteria in the medium at the initiation of aeration are 1.0 x 1010 cfu/ml (10.0 log cfu/ml) or more, preferably 1.4 * 1010 cfu/ml (10.1 log cfu/ml) or more. By such an operation, carbon sources in the medium can be almost used up. In the medium containing lactose and under the culture condition described hereinabove, the concentration of lactose reaches 3 . 5% by mass or less at about 48 hours after initiating the culture, and it is the time for initiating the aeration. Although a culture method by which saccharide for carbon source such as lactose and glucose is added for propionic acid bacteria in the course of cultivation has been known (e.g. Patent document 1: JP-A-10-304871), such saccharides are preferably consumed in the present invention without adding in the course of culturing. <br><br>
Amount of air to be supplied by aeration is preferably the amount sufficient to stimulate propionic acid bacteria. Specific example of such a condition corresponding to a laboratory scale (volume 1.5 lit.) is mentioned as follows ._ When the culture is performed under the condition using sparger with stirring propeller at 150 rpm, amount of supplied air is 2 lit. or more/min., preferably 2 lit./min. to 4 lit./min., and can be adjusted properly in conformity to the volume, stirring rate, apparatus, etc. When dissolved oxygen in the liquid becomes high beyond necessity, proliferation of propionic acid bacteria is terminated and production of DHNA is also terminated. In the case of the medium and the culture <br><br>
546286 <br><br>
- 10 - <br><br>
condition hereinbefore, the culture is generally terminated at about 168 hours from the initiation of the culture. <br><br>
Aeration method includes a method for supplying air from whole surface of tube by inserting the porous aeration tube in the medium, or a method for supplying air bubble by using sparger. <br><br>
The thus accumulated DHNA in the medium and microbial cells can be collected from the culture immediately after termination of the culture. Terminal point of the culture can be determined roughly on 3 to 5 days after numbers of microbial cells reaches the stationary phase and the carbon source in the medium has been used up. <br><br>
The method for producing DHNA by adding carbon source for propionic acid bacteria to the culture after termination of the culture and preserving at 3 to 20°C under weak alkaline conditions will be explained hereinbelow. The culture herein can be the culture after performing the aeration hereinbefore, but it may be the culture after termination of the culture under the condition of conventional anaerobic or slightly aerobic condition without aeration process. <br><br>
Amount of carbon source to be added to the culture is preferably set to 0.2 to 3.0% by mass, preferably 0.4 to 2.5% by mass, more preferably 0.8 to 2.2% by mass of concentration of the carbon source in the culture. Further, weak alkaline condition can be maintained to pH 7 to 9, preferably pH 7 .5 to 8.5 by adding base such as potassium carbonate, sodium carbonate and sodium phosphate. Preservation temperature is 3 to 20°C, preferably 3 to 15°C, more preferably 5 to 15°C. <br><br>
546286 <br><br>
- 11 - <br><br>
Preservation term is preferably 1 to 3 weeks, more preferably 1 to 2 weeks. <br><br>
Content of DHNA in the culture can be improved by preservation at low temperature under such weak alkaline condition. The method of the present invention without necessitating new facilities, with small-space and with maintaining increased amount of DHNA during the preservation can be said as extremely useful and effective method for production. <br><br>
A method for collecting DHNA will be explained hereinbelow. The obtained culture is preferably subjected to adsorption chromatography. Actj_vat-ecj charcoal and reverse phase adsorbing agents such as synthetic adsorbing agent (e.g. Diaion HP-20, Mitsubishi Chemical. Corp.) as examples of adsorbing agent can be used widely. Adsorbing agent is filled in a column and washed with aqueous sodium ascorbate 0.5% by weight solution. The obtained culture is added on a column (a liquidpassed through the column is defined as "PASS") and the column is washed with aqueous sodium ascorbate 0.5% by weight solution to remove water soluble fraction. Thereafter, a solution of sodium ascorbate 0.5% by weight in ethanol is passed through the column for elution, and the eluted fraction of the ethanol solution is concentrated to obtain the composition containing high concentration of DHNA. Pure DHNA or salt thereof can be obtained by performing further purification. Methanol and other alcohol in place of ethanol can be used for eluting DHNA from the column. Further, as for the method replacing the above, isolation <br><br>
546286 <br><br>
- 12 - <br><br>
of DHNA can be performed by using liquid chromatography from the supernatant collected by centrifugation of the culture. Sodium erythorbate can be preferably used in place of sodium ascorbate. These compounds can be used as stabilizing agent for DHNA, and in the present invention, ascorbic acid, erythorbic acid, free acid thereof, fatty ester and other various esters, alkali metal salts, and other salts can also be used. <br><br>
Examples of salt of DHNA are pharmaceutically or dietetically acceptable salts thereof, and representative salts include monovalent metal salt such as sodium, potassium, lithium, multivalent metal salt such as magnesium, calcium, zinc, and inorganic or organic amine salt such as ammonia and ethanolamine. Salt exchange can be performed by using known reaction. Examples of such salts are salt with inorganic acid (e.g. hydrochloric acid, phosphoric acid, hydrobromic acid and sulfuric acid) , or salt with organic acid (e.g. formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoicacid, raethanesulfonic acidandbenzenesulfonic acid) . These are illustrative only and the present invention is not limited to such salts. <br><br>
Since DHNA is contained in the culture of DHNA producing bacteria (intra-microbial cells and/or extra-microbial cells) , the culture itself can be concentrated by using rotary evaporator without applying adsorption chromatography to obtain the composition containing high concentration of DHNA. Separation of microbial cells from the culture by using <br><br>
546286 <br><br>
- 13 - <br><br>
conventional centrifugation and concentration of the obtained supernatant is preferable. The thus obtained composition can be used in the form of liquid state in conformity to a desired form for utilization or can be processed to powder state. <br><br>
The thus obtained composition containing DHNA has high concentration of DHNA with suppressed bitter taste and good flavor. Consequently, the composition containing DHNA, or DHNA or salt thereof can be utilized in any forms of food and beverages or pharmaceuticals. For example, improvement of intestinal flora or reducing abdominal discomfort observed in ingestion of milk, and prevention and treatment of metabolic osteopathy can be achieved by administering directly as the pharmaceuticals, or by directly ingesting food for special dietary use such as food for specified health use, or food with nutrient function claims, or by ingesting various foods (milk, refreshment, fermented milk, yoghurt, cheese, bread, biscuit, cracker, pizza, crust and others) added therewith. <br><br>
In the production of foods described above, water, protein, saccharides, lipids, vitamins and minerals, organic acids, fruit juice, flavor, etc can be added in combination as a main component. For example, animal and plant proteins such as dry whole milk, skim milk, partially-skimmed milk, casein, whey powder, whey protein, whey protein concentrate, whey protein separate, a-casein, p-casein, p-lactoglobulin, a-lactalbumin, lactoferrin, soybean protein, egg protein, meat protein, etc., hydrolyzate thereof, various milk derived components such as butter, whey mineral, cream, whey, nonprotein nitrogen, sialic acid, phospholipids and lactose; <br><br>
546286 <br><br>
- 14 - <br><br>
carbohydrates such as sucrose, glucose, fructose, sugar alcohols, malt sugar, oligosaccharides, processed starch (dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.) and dietary fiber; animal oil and fat such as lard and fish oil; vegetable oil such as palm oil, safflower oil, corn oil, canola oil, copra oil, etc. and vegetable oil such as fractionated oil, hydrogenated oil, ester exchanged oil, etc.; various vitamins such as vitamin A, vitamin B group, vitamin C, erythorbic acid, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline, folic acid, etc.; minerals such as calcium, potassium, magnesium, sodium, chlorine, copper, iron, manganese, zinc, selenium, fluorine, silicon, iodine, etc.; and organic acid such as malic acid, citric acid, lactic acid, tartaric acid and salt thereof can be mentioned, and one or two or more selected therefrom can be properly selected and added. Various components thereof can be preferably added in the form of synthetic products and if necessary in the form of foods containing large amounts thereof. The form thereof is not specifically limited to the aforementioned foods and is not limited if the final products maintain activity, and any forms such as liquid, solid (including granules, powder, tablets and gelled substance}, semisolid substance (including jellied products), paste, emulsion, etc. can be used. <br><br>
When the composition, or DHNA or salt thereof of the present invention is used as pharmaceuticals, it can be administered in various forms. Oral administration in the <br><br>
546286 <br><br>
- 15 - <br><br>
form of, for example, tablets, capsules, granules, powdered medicine, syrup, etc. can be mentioned. Such the pharmaceutical preparation can be formulated by using the main ingredient and the known auxiliary substances conventionally used in the pharmaceutical formulation technical field such as diluents, binders, disintegrators, lubricants, corrigents, solubilizing agents, suspensions, coating agents, etc. <br><br>
Examples <br><br>
The present invention will be explained hereinbelow by mentioning Test Examples and examples, but the present invention is not limited by them. In the Test Examples and examples hereinbelow, quantitative determination of DHNA was performed according to the method described in WO 03-016544, page 9. Measurement of concentration of lactose was performed by flow injection analysis using lactose electrode (Oji Scientific Instruments, Flow injection analyzer, Bio Flow Analyzer (Tradename)) . The number of propionic acidbacteria was measured in a BL agar medium. Concentration of propionic acid and acetic acid were measured by HPLC (column: RS pak KC-811+precolum KC-G, detection: UV 445 nm) . <br><br>
Test Example 1 <br><br>
Examination on various aeration initiation times (1) Preparation of medium <br><br>
Skim milk (Meiji Dairies Corp.) 150 g was dissolved in 1000 g of water and the temperature of the solution was adjusted at 47°C. Protease 3.75 g was added thereto to hydrolyze protein at 47°C for 6 hours. The pH of the reaction mixture <br><br>
546286 <br><br>
- 16 - <br><br>
during protein hydrolysis was adj us ted to 6.6 to 6.8 by using aqueous potassium carbonate solution. After the hydrolysis of protein, the reaction mixture was maintained at 80°C for 10 minutes to inactivate protease, supplied with beer yeast extract 7.5 g and adjusted at pH 6. 95 using aqueous potassium carbonate solution. The volume of solution was adjusted to 1500 ml by adding water, and the solution was poured into a 2 lit. fermenter, and then the medium was sterilized. Sterilization condition was set at 121°C for 7 minutes. (2) Culture condition <br><br>
Nitrogen gas was ventilated through the fermenter, and the temperature of the medium was stabilized at 33°C, then the freeze concentration starter (P. freudenreichii et-3) 0.75 ml was added to initiate culturing. Temperature during fermentation was adjusted at 33°C and pH was adjusted to 6.5, and nitrogen gas was ventilated. Adjustment of pH was performed using 40% by weight aqueous potassium carbonate solution. Atotal of five culturingmethods as describedbelow was performed. <br><br>
1) Continuing nitrogen gas ventilation from initiation till termination of culturing; <br><br>
2) Same as in the above 1) except that lactose 2% by weight was added after 72 hours and 96 hours from initiation of culturing; <br><br>
3) Nitrogen gas ventilation was switched to aeration (2 lit./min.) after 24 hours from initiation of culturing; <br><br>
4) Ventilation was switched to the aeration (2 lit./min.) after 48 hours from initiation of culturing; and <br><br>
546286 <br><br>
- 17 - <br><br>
5) Ventilation was switched to the aeration (2 lit./min.) after 72 hours from initiation of the culture. <br><br>
These were all terminated after 168 hours from initiation of the culture. <br><br>
(3) Results <br><br>
Changes in a time-dependent manner of concentration of DHNA, concentration of lactose, numbers of propionic acid bacteria, concentration of propionic acid, and concentration of acetic acid are shown in Figure 1, Figure 2, Figure 3, Figure 4 and Figure 5, respectively. As obvious from the results, the culture obtained in 4) and 5) showed that the concentration of DHNA was about 45 pi/ml (Figure 1) . In 4) and 5), lactose was almost used up after 96 hours (Figure 2), and a concentration of propionic acid which has been increased from initiation of the culture was confirmed to have gradually decreased (Figure 4) . Numbers of propionic acid bacteria exceeded in all the example culturing conditions except 3) to above 1.0 * 1010 cfu/ml (10.0 log cfu/ml), and reached about 1.0 * 1011 cfu/ml (11.0 log cfu/ml) in 4) and 5) (Figure 3). <br><br>
From the above results, it was confirmed that the culture containing high concentration of DHNA could be obtained by switching from the nitrogen gas ventilation to aeration at least after 48 hours passing from initiation of the culture (Figure 6). In addition, concentrations of lactose at the time of switching were 3.3% by mass in 4) and 2.9% by mass in 5) (Figure 2). <br><br>
Test Example 2 <br><br>
546286 <br><br>
- 18 - <br><br>
Examination on aeration volume <br><br>
Culture was performed by the same condition as in Test Example 1, 5) except for changing the aeration volume. Aeration volume was changed to 0 . 5 lit. /min. , 1.0 lit. /min ., 2.0 lit. /min. and 4.0 lit. /min. after 72 hours from initiation of the fermentation. As a result, it was found that concentration of DHNA reached about 40 iig/ml after 144 hours from initiation of the culture by maintaining the flow rate at 2.0/min. or more. <br><br>
Example 1 <br><br>
Skim milk (Meiji Dairies Corp.) 180 g was dissolved in water 1000 g and the solution was adjusted in temperature at 47°C. Protease 3.75 g was added thereto to hydrolyze protein at 47°C for 3 hours. pH of the reaction mixture during protein hydrolysis was adjusted to pH 6.6 to 6.8 by using aqueous potassium carbonate solution. After the hydrolysis of protein, the reaction mixture was heated to 80°C and maintained for 10 minutes to inactivate protease, supplied with beer yeast extract 7.5 g and lactose 15 g, and adjusted at pH 6.95 by using aqueous potassium carbonate solution. A volume of solution was adjusted to 1500 ml by adding water, the solution was poured into the 2 lit. volume fermenter, and the medium was sterilized (concentration of lactose about 6.1% by mass) . Sterilization condition was set at 121°C for 7 minutes. After the sterilization, nitrogen gas was ventilated through the fermenter, and temperature of the medium was stabilized at 33°C, then the freeze concentration starter (P. f reudenreichii ET-3) 0.75 ml was added to initiate <br><br>
546286 <br><br>
- 19 - <br><br>
the culture. Temperature during fermentation was adjusted at 33°C and pH was adjusted to pH 6.5, and nitrogen gas was ventilated. Adjustment of pH was performed using 4 0% by weight aqueous potassium carbonate solution. Ventilation of nitrogen gas was switched to the aeration after 72 hours from initiation of the culture, and the culture was terminated after 168 hours from initiation of the culture . Aeration rate of air at the aeration was set to 2 lit./min. and agitation rate was set to 150 rpm. As a result, the culture with concentration of DHNA 52 yg/ml could be obtained. Concentration of lactose after 72 hours was about 1.9% by mass and numbers of propionic acid bacteria were 3.5 x 1Q10 cfu/ml. <br><br>
Example 2 <br><br>
Skim milk (Meiji Dairies Corp.) 120 kg was dissolved in water 7 50 kg and the solution was adjusted in temperature at 47°C. Protease 2 . 5 kg was added thereto, and the mixture was adjusted to pH 7.6 to hydrolyze protein at 47°C for 3 hours. After the hydrolysis was completed, the reaction mixture was heated to 80°C and maintained for 10 minutes to inactivate protease, supplied with beer yeast extract 5 kg and lactose 10 kg, and the medium was sterilized at 140°C for 4 seconds. pH of the medium before initiation of the sterilization was pH 6. 9. After the sterilization, the volume of the medium was adjusted to 1000 lit. by adding water (concentration of lactose about 6.1% by mass), and nitrogen gas was ventilated at 20 lit./min. through the fermenter, and temperature of the medium was stabilized at 33°C, then <br><br>
546286 <br><br>
- 20 - <br><br>
the starter (P. freudenreichii ET-3) 3.0 lit. was added. Temperature during fermentation was adjusted at 33°C and pH was adjusted to 6.5, and nitrogen gas was ventilated. Adjustment of pH was performed using 23% by weight aqueous potassium carbonate solution. Ventilation of nitrogen gas was switched to the aeration after 72 hours from initiation of the culture, and the culture was terminated after 168 hours from initiation of the culture. Air mass flow at the aeration was set to 200 lit./min. and agitation rate was set to 52 rpm. As a result, the culture with concentration of DHNA 42 tag/ml could be obtained. Concentration of lactose after 72 hours from initiation of the culture was about 1.5% by mass and numbers of propionic acid bacteria were 3.0 x io10 cfu/ml. Example 3. <br><br>
To the culture containing DHNA obtained in example 2 hereinabove was added sodium ascorbate 1. 0% and lactose 2.0%, and the pH of the mixture was adjusted to 8.0, and preserved at 10°C for 2 weeks to obtain concentration of DHNA 55 jig/ml. <br><br>
Lactose was replaced by glucose and the mixture was preserved in a same manner as above, and as a result, concentration of DHNA was increased compared to that at the time of termination of the culture. <br><br>
Comparative Example <br><br>
The culture was performed in the same condition as in example 1, except that aeration was not switched and nitrogen gas ventilation was continued during the culture . As a result, the culture with concentration of DHNA 32 pg/ml was obtained. Example 4 <br><br>
546286 <br><br>
- 21 - <br><br>
Results of sensory evaluation of yoghurt prepared by adding the culture containing DHNA obtained in example 1 hereinbefore to plane yoghurt 120 g (Meiji Dairies Corp.) are shown in Table 1 and Table 2. It was confirmed that the yoghurt with the added culture containing DHNA obtained by the method of the present invention had high concentration of DHNA, and had neither acid taste nor bitter taste as compared with yoghurt prepared by the conventional method (i.e. to the plane yoghurt was added the culture containing DHNA obtained by Comparative Example). <br><br>
[Table 1] <br><br>
Item <br><br>
Flavor <br><br>
Acid taste <br><br>
Bitter taste <br><br>
Overall j udgment <br><br>
Culture prepared in Example 1 <br><br>
Good <br><br>
Good <br><br>
None <br><br>
Very Good <br><br>
Culture prepared in Comparative Example <br><br>
Good <br><br>
Good <br><br>
Bad <br><br>
Fair <br><br>
1 g added to plane yoghurt <br><br>
Plane yoghurt: 120 <br><br>
g <br><br>
[Table 2] <br><br>
Item <br><br>
Flavor <br><br>
Acid taste <br><br>
Bitter Overall taste judgment <br><br>
Culture prepared in Example 1 <br><br>
Fair <br><br>
Good <br><br>
None <br><br>
Good <br><br>
Culture prepared in Comparative Example <br><br>
Fair <br><br>
Fair <br><br>
Bad <br><br>
Bad <br><br>
2 g added to plane yoghurt <br><br>
Plane yoghurt: 120 g <br><br>
Example 5 <br><br>
546286 <br><br>
- 22 - <br><br>
Skim milk (Meiji Dairies Corp.) 120 kg was dissolved in water 7 50 kg and the solution was adjusted in temperature at 47°C. Protease 2 . 5 kg was added thereto, pH of the solution was adjusted to pH 7.6 to hydrolyze protein at 47°C for 6 hours. After the hydrolysis was completed, the reaction mixture was heated to 80°C and maintained for 10 minutes to inactivate protease, supplied with beer yeast extract 5 kg and lactose 10 kg, and the medium was sterilized at 140°C for 4 seconds. pH of the medium before initiation of the sterilization was 6.9. After the sterilization, a volume of the medium was adjusted to 1000 lit. by adding water (concentration of lactose about 6.1% by mass), and nitrogen gas was ventilated at 20 lit./min. through the fermenter, and temperature of the medium was stabilized at 33°C, then the starter (P. freudenreichii ET-3) 3.0 lit. was added. Temperature during fermentation was adjusted at 33°C and pH was adjusted to pH 6.5, and nitrogen gas was ventilated. Adjustment of pH was performed using 23% by weight aqueous potassium carbonate solution. Ventilation of nitrogen gas was switched to the aeration after 72 hours from initiation of the culture, and the culture was terminated after 168 hours from initiation of the culture. Air mass flow at the aeration was set to 200 lit./min. and agitation rate was set to 52 rpm. As a result, the culture with concentration of DHNA 48 pg/ml could be obtained. Concentration of lactose after 72 hours from initiation of the culture was about 3.0% by mass and numbers of propionic acid bacteria were 2.9 x 1010 cfu/ml. Example 6 <br><br>
546286 <br><br>
- 23 - <br><br>
To the culture containing DHNA obtained in example 5 hereinabove was added sodium ascorbate 1. 0% and lactose 1.0%, the mixture was adjusted in pH to 8.0 and preserved at 10°C for 2 weeks to obtain concentration of DHNA 60 tig/™!- <br><br></p>
</div>
Claims (10)
1. A process for producing 1,4-dihydroxy-2-naphthoic acid comprising initiating the culture of 1,4-dihydroxy-2-<br><br> 5 naphthoic acid producing bacteria belonging to propionic acid bacteria in a medium comprising 4 to 8 % mass of a carbon source under anaerobic conditions and culturing the bacteria under aeration into the medium when the concentration of a carbon source in the medium is 3.5% by 10 mass or less.<br><br>
2. The process according to claim 1, wherein the anaerobic conditions are conditions under nitrogen gas or carbon dioxide gas atmosphere.<br><br>
3. A process for producing 1,4-dihydroxy-2-naphthoic acid, comprising initiating the culture of 1,4-dihydroxy-2-naphthoic acid producing bacteria belonging to propionic acid bacteria in a medium comprising 4 to 81 by mass of a<br><br> 20 carbon source under anaerobic conditions, culturing the bacteria under aeration into the medium when the concentration of a carbon source in the medium is. 3.5% by mass or less, adding the carbon source to the obtained culture and preserving the culture at 3 to 20°C under weak<br><br> 25 alkaline conditions.<br><br>
4. The process according to claim 3, wherein the anaerobic conditions are conditions under nitrogen gas or carbon dioxide gas atmosphere.<br><br>
5. The process according to claim 3 or 4, wherein the amount of carbon source added to the culture is such that<br><br> 15<br><br> 30<br><br> W:\SEW\NZ147l8-06 (GYC)Mst respons^c1aim&-01080S.doc<br><br> 546286<br><br> 25<br><br> a concentration of the carbon source in the culture is 0.2 to 3% by mass.<br><br>
6. The process according to claim 3 or 4, wherein the 5 culture is preserved at pH 7 to 9 at 3 to 20°C for 1 to 3<br><br> weeks.<br><br>
7. A composition comprising 1,4-dihydroxy-2-naphthoic acid obtained by the process according to any one of<br><br> 10 claims 1 to 6.<br><br>
8. Food and beverages for improving abdominal discomfort, comprising the composition according to claim 7 as an active ingredient.<br><br> 15<br><br>
9. An agent for improving abdominal discomfort, comprising the composition according to claim 7 as an active ingredient.<br><br> 20
10. Food and beverages for preventing and treating metabolic osteopathy, comprising the composition according to claim 7 as an active ingredient.<br><br>
11. An agent for preventing and treating metabolic 25 osteopathy, comprising the composition according to claim<br><br> 7 as an active ingredient.<br><br>
12. Use of the composition according to claim 7 for producing food and beverages for improving abdominal<br><br> 30 discomfort.<br><br>
13. Use of the composition according to claim 7 for producing an agent for improving abdominal discomfort.<br><br> W:\SEW\NZ14718-06 (GYC)\1St response\claims-010808.doc 1 Orrt^c i 1 6 sep 2008<br><br> 546286<br><br> 26<br><br>
14. Use of the composition according to claim 7 for producing food and beverages for preventing and treating metabolic osteopathy.<br><br> 5<br><br>
15. Use of the composition according to claim 7 for producing an agent for preventing and treating metabolic osteopathy.<br><br> 10 16. 1,4-dihydroxy-2-naphthoic acid, prepared by the process of claim 1 or claim 3.<br><br>
17. A process for producing 1,4-dihydroxy-2-naphthoic acid according to claim 1 or claim 3, substantially as 15 hereinbefore described with reference to any one of Examples 1 to 6.<br><br> W:\SEWWZ14716-Q5 (GYQUst respon&e\claims-O10e0e.t»oc<br><br> </p> </div>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003343211 | 2003-10-01 | ||
PCT/JP2004/014394 WO2005033323A1 (en) | 2003-10-01 | 2004-09-30 | Process for producing 1,4-dihydoxy-2-naphthoic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ546286A true NZ546286A (en) | 2008-10-31 |
Family
ID=34419286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ546286A NZ546286A (en) | 2003-10-01 | 2004-09-30 | Process for producing 1,4-dihydroxy-2-naphthoic acid |
Country Status (9)
Country | Link |
---|---|
US (2) | US7507563B2 (en) |
EP (3) | EP2463375B1 (en) |
JP (1) | JP4613132B2 (en) |
KR (1) | KR101116244B1 (en) |
CN (1) | CN100422337C (en) |
AU (1) | AU2004278620B2 (en) |
CA (1) | CA2540507C (en) |
NZ (1) | NZ546286A (en) |
WO (1) | WO2005033323A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100087078A (en) * | 2007-11-27 | 2010-08-03 | 메이지뉴교오가부시기가이샤 | Agent and method for improving survivability of lactic acid bacterium, and food composition |
WO2009107380A1 (en) * | 2008-02-29 | 2009-09-03 | 明治乳業株式会社 | Anti-allergic agent |
US11179427B2 (en) | 2013-01-21 | 2021-11-23 | Eth Zurich | Baby food composition comprising viable propionic acid-producing bacteria |
WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
CN111227038B (en) * | 2018-11-29 | 2023-02-24 | 内蒙古伊利实业集团股份有限公司 | Double-fermentation double-protein milk beverage and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3315826B2 (en) * | 1994-04-26 | 2002-08-19 | 明治乳業株式会社 | Bifidobacterium growth promotion composition |
ES2102332B1 (en) * | 1996-01-03 | 1998-03-01 | Invest Y Desarrollo Agroindust | PROCEDURE FOR THE PRODUCTION OF VITAMIN B12 FROM CONTAMINATING WASTE FROM THE CITRICULTURAL INDUSTRIES. |
JP3017456B2 (en) | 1997-05-08 | 2000-03-06 | 明治乳業株式会社 | High-concentration culture method and culture product of propionic acid bacteria and processed product thereof |
WO2000037669A2 (en) * | 1998-12-18 | 2000-06-29 | Dsm N.V. | Non-continuous process for the production of vitamin b12 |
EP1416052B8 (en) * | 2001-08-10 | 2013-01-09 | Meiji Co., Ltd. | Process for producing 1,4-dihydroxy-2-naphthoic acid |
CN1764627B (en) * | 2003-03-26 | 2016-05-25 | 株式会社明治 | The method of stabilizing 1,4-dihydroxy-2-naphthoic acid |
-
2004
- 2004-09-30 CN CNB2004800284544A patent/CN100422337C/en active Active
- 2004-09-30 NZ NZ546286A patent/NZ546286A/en unknown
- 2004-09-30 EP EP12001429.5A patent/EP2463375B1/en not_active Not-in-force
- 2004-09-30 US US10/574,283 patent/US7507563B2/en active Active
- 2004-09-30 EP EP04788422.6A patent/EP1669458B1/en not_active Not-in-force
- 2004-09-30 JP JP2005514449A patent/JP4613132B2/en not_active Expired - Fee Related
- 2004-09-30 CA CA2540507A patent/CA2540507C/en active Active
- 2004-09-30 EP EP12001430.3A patent/EP2463376B1/en not_active Not-in-force
- 2004-09-30 WO PCT/JP2004/014394 patent/WO2005033323A1/en active Application Filing
- 2004-09-30 AU AU2004278620A patent/AU2004278620B2/en not_active Ceased
-
2006
- 2006-03-29 KR KR1020067006133A patent/KR101116244B1/en active IP Right Grant
-
2008
- 2008-08-06 US US12/187,065 patent/US8758842B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP4613132B2 (en) | 2011-01-12 |
EP1669458A1 (en) | 2006-06-14 |
EP2463375B1 (en) | 2019-08-21 |
KR20060087594A (en) | 2006-08-02 |
WO2005033323A1 (en) | 2005-04-14 |
EP2463375A2 (en) | 2012-06-13 |
CA2540507A1 (en) | 2005-04-14 |
CA2540507C (en) | 2015-09-29 |
US20070066685A1 (en) | 2007-03-22 |
EP2463376A2 (en) | 2012-06-13 |
AU2004278620A1 (en) | 2005-04-14 |
US8758842B2 (en) | 2014-06-24 |
AU2004278620B2 (en) | 2010-07-15 |
US20090232940A1 (en) | 2009-09-17 |
KR101116244B1 (en) | 2012-03-09 |
EP2463376A3 (en) | 2013-01-30 |
EP1669458B1 (en) | 2016-03-16 |
EP1669458A4 (en) | 2011-05-25 |
US7507563B2 (en) | 2009-03-24 |
EP2463375A3 (en) | 2013-01-30 |
EP2463376B1 (en) | 2019-08-28 |
CN100422337C (en) | 2008-10-01 |
CN1860236A (en) | 2006-11-08 |
JPWO2005033323A1 (en) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8025911B2 (en) | Preventive and/or remedy for inflammatory bowel diseases | |
CN1312285C (en) | Process for producing 1,4-dihydroxy-2-naphthoic acid | |
US8758842B2 (en) | Process for producing 1,4-dihydroxy-2-naphthoic acid | |
JPH06205652A (en) | Preparation of nutrition promoting shiitake agent | |
JP2000210075A (en) | Lactic acid bacterium having high productivity of gamma- aminobutyric acid, fermented food with high content of gamma-aminobutyric acid using the same lactic acid bacterium and its production | |
JP6005453B2 (en) | Composition comprising ornithine and equol | |
TWI502070B (en) | Production method of γ-butyric acid | |
JP5603036B2 (en) | Probiotic growth promoter | |
JPH0940566A (en) | Treating agent for diabetic and immunopotentiator produced from lactobacillus fermentation product | |
WO2017141879A1 (en) | Pancreatic lipase inhibitor composition and production method for pancreatic lipase inhibitor composition | |
JP6674514B2 (en) | Process for producing food or its precursor, food or its precursor and corresponding use | |
JP7484030B2 (en) | Method for producing an inclusion complex in which equol is included in cyclodextrin | |
Sharma et al. | AMELIORATION IN THE NUTRITIONAL CONTENT OF CURD PREPARED USING PROBIOTIC YEAST SACCHAROMYCES CEREVISIAEID18 | |
JP2003088335A (en) | Food composition for improving urination function, and good and drink containing the same | |
JP2011120502A (en) | Choline highly-containing yeast and choline highly-containing yeast crushed product, and food | |
JPH02299582A (en) | Proliferation promoting agent and production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 30 SEP 2024 BY PHILLIPS ORMONDE FITZPATRICK Effective date: 20140815 Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 SEP 2017 BY PHILLIPS ORMONDE FITZPATRICK Effective date: 20140815 |